PressOctober 13, 2022 Relmada Therapeutics Announces Top-line Results from Phase 3 RELIANCE III Trial for REL-1017 as a Monotherapy for the Treatment of Major Depressive Disorder
PressOctober 13, 2022 Clairvoyant’s Phase 2 Psilocybin Therapy Trial for Alcohol Use Disorder Obtains Regulatory Approval and Initiates 1st Clinical Site in Finland
PressOctober 12, 2022 COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day
PressOctober 12, 2022 atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
PressOctober 12, 2022 Enveric Biosciences Announces Poster Presentations of Lead Programs at the 2022 International Neurology & Brain Disorders Conference
PressOctober 12, 2022 Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics Conference
PressOctober 11, 2022 PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical Trial
PressOctober 10, 2022 Silo Pharma’s Mission To Merge Traditional Pharmaceuticals With Psychedelic Compounds Can Be A Treatment Game-Changer For Neurological Disorders
PressOctober 10, 2022 Core One Labs Nearing GMP Production as Canada’s Province of Alberta Announces Game Changing Legislation
PressOctober 10, 2022 ALTRD.TV’s Open Minds Documentary Explores the Promising Future of Psychedelic Medicine
PressOctober 10, 2022 Silo Pharma Initiates Toxicity Study of its Proprietary Ketamine Formulation for Treatment of Fibromyalgia
PressOctober 7, 2022 Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022
PressOctober 7, 2022 Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
PressOctober 6, 2022 Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12
PressOctober 6, 2022 Wellbeing Subsidiary KGK Science Announces Psilocybin Microdose Capsule Formulation to be Submitted to Health Canada for Phase 2A Trial
